ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0851

Application of a Modified Recursive Feature Elimination Machine Learning Algorithm to Select Predictors of Mortality in Those with and Without Osteoarthritis

Research Methodology Poster (0846–0854)

8:30AM-10:30AM: Abstract Number: 0746

Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0794

Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0812

Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0751

Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0905

Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Abstract Number: 0657

Assessing Patient Transition Outcomes from a Large Pediatric Rheumatology Center to Adult Healthcare

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0681

Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0654

Assessing Provider Knowledge and Opinions of the 2017 Guidelines for Perioperative Management of Antirheumatic Medications in a Single Academic Center

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0637

Assessing the Rates of Cervical Cancer Screening in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0741

Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0749

Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0580

Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0611

Association of Area Deprivation Index and Practice Patterns of Medicare Part D Rheumatologists

Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Abstract Number: 0717

Association of Fatigue with Disease Activity in Myositis

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].